Figure 4.
OS and cumulative incidence of HM among subjects with biallelic ERCC6L2 variants. (A) Kaplan-Meier curves displaying the OS of patients with biallelic ERCC6L2 variants and initial diagnosis of BMF, MDS, or AML, including 1 patient with T-ALL progressing to MDS/AML in this patient group. (B) Onset of HM based on age (n = 48). (C) Onset of HM, based on age, in subjects with and without the homozygous mutation of ERCC6L2 1424delT (Finnish founder mutation). (D) OS of patients with biallelic ERCC6L2 variants and allogeneic HSCT per the diagnosis while receiving a transplant.

OS and cumulative incidence of HM among subjects with biallelic ERCC6L2 variants. (A) Kaplan-Meier curves displaying the OS of patients with biallelic ERCC6L2 variants and initial diagnosis of BMF, MDS, or AML, including 1 patient with T-ALL progressing to MDS/AML in this patient group. (B) Onset of HM based on age (n = 48). (C) Onset of HM, based on age, in subjects with and without the homozygous mutation of ERCC6L2 1424delT (Finnish founder mutation). (D) OS of patients with biallelic ERCC6L2 variants and allogeneic HSCT per the diagnosis while receiving a transplant.

Close Modal

or Create an Account

Close Modal
Close Modal